Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Theravance Biopharma's FCF Margin % or its related term are showing as below:
TBPH'
s FCF Margin % Range Over the Past 10 Years
Min: -1322.36 Med: -268.33 Max: 244.85
Current: 244.85
During the past 13 years, the highest FCF Margin % of Theravance Biopharma was 244.85%. The lowest was -1322.36%. And the median was -268.33%.
TBPH's FCF Margin % is ranked better than 99.68% of 952
companies
in the Biotechnology industry
Industry Median: -82.715
vs TBPH: 244.85
Theravance Biopharma FCF Margin % Related Terms
Theravance Biopharma FCF Margin % Historical Data
* Premium members only.
The historical data trend for Theravance Biopharma's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Theravance Biopharma's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Theravance Biopharma FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Theravance Biopharma's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Theravance Biopharma's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Theravance Biopharma (TBPH) has a FCF Margin % of 414.03% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Theravance Biopharma and its competitors. According to the industry distribution chart, Theravance Biopharma ranks #3 out of 952 companies in the Biotechnology industry, placing it in the top 0.3%.
Is Theravance Biopharma's FCF Margin % too high?
Theravance Biopharma's current FCF Margin % is 414.03%. Based on the distribution chart, Theravance Biopharma ranks #3 out of 952 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Theravance Biopharma has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Theravance Biopharma's FCF Margin % compare to ABUS and SANA?
According to the Biotechnology industry distribution chart, Theravance Biopharma ranks #3 out of 952 companies for FCF Margin %. This places Theravance Biopharma in the top 0% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Theravance Biopharma and its competitors. Theravance Biopharma's current FCF Margin % is 414.03%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Theravance Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Theravance Biopharma (TBPH) is currently considered Modestly Undervalued. The stock's GF Value™ is $18.67, compared to a current price of $16.86 — trading 9.7% below its estimated fair value. The current FCF Margin % is 414.03%. Theravance Biopharma's overall GF Score™ is 72/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Theravance Biopharma (TBPH), the current FCF Margin % is 414.03% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Theravance Biopharma (TBPH) Overvalued in 2026?
Based on GuruFocus' analysis, Theravance Biopharma stock appears to be undervalued.
The current stock price of $16.86 is trading 9.7% below its estimated GF Value™ of $18.67.
GuruFocus considers Theravance Biopharma to be Modestly Undervalued.
Key valuation signals for TBPH:
FCF Margin %: 414.03%
GF Value™: $18.67 vs. price of $16.86 (9.7% below fair value)
No single metric tells the full story. See the TBPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.
72GF Score
Get the complete analysis for TBPH
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TBPH has been successfully added to your 
